BR0016415A - Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico - Google Patents

Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico

Info

Publication number
BR0016415A
BR0016415A BR0016415-1A BR0016415A BR0016415A BR 0016415 A BR0016415 A BR 0016415A BR 0016415 A BR0016415 A BR 0016415A BR 0016415 A BR0016415 A BR 0016415A
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
optic nerve
treatment
retinal
nerve damage
Prior art date
Application number
BR0016415-1A
Other languages
English (en)
Inventor
Peter G Klimko
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0016415A publication Critical patent/BR0016415A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"INIBIDORES DE ADENOSINA CINASE PARA O TRATAMENTO DE DANO RETINAL E DE NERVO óTICO". A presente invenção refere-se a um processos para a prevenção e tratamento de dano para o nervo ótico e/ou retina com inibidores de adenosina cinase são mostrados.
BR0016415-1A 1999-12-16 2000-11-28 Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico BR0016415A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17106899P 1999-12-16 1999-12-16
PCT/US2000/032376 WO2001043731A2 (en) 1999-12-16 2000-11-28 Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage

Publications (1)

Publication Number Publication Date
BR0016415A true BR0016415A (pt) 2002-12-24

Family

ID=22622381

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016415-1A BR0016415A (pt) 1999-12-16 2000-11-28 Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico

Country Status (9)

Country Link
US (1) US20050282769A1 (pt)
EP (1) EP1250128A2 (pt)
JP (1) JP2003516962A (pt)
AU (1) AU1929801A (pt)
BR (1) BR0016415A (pt)
CA (1) CA2390821A1 (pt)
HK (1) HK1048439A1 (pt)
MX (1) MXPA02005959A (pt)
WO (1) WO2001043731A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
ES2655028T3 (es) 2007-08-02 2018-02-16 Millennium Pharmaceuticals, Inc. Proceso para la síntesis de inhibidores de enzima de activación de E1
SI2516434T1 (sl) 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
CA3107640A1 (en) 2011-12-22 2013-06-27 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EA201890454A1 (ru) 2015-08-06 2018-07-31 Чимерикс, Инк. Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
US11111264B2 (en) 2017-09-21 2021-09-07 Chimerix, Inc. Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
US4912092A (en) * 1986-03-27 1990-03-27 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
DE3773926D1 (de) * 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
US5864033A (en) * 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
WO1994018215A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage

Also Published As

Publication number Publication date
JP2003516962A (ja) 2003-05-20
CA2390821A1 (en) 2001-06-21
HK1048439A1 (zh) 2003-04-04
AU1929801A (en) 2001-06-25
WO2001043731A2 (en) 2001-06-21
US20050282769A1 (en) 2005-12-22
EP1250128A2 (en) 2002-10-23
WO2001043731A3 (en) 2002-03-21
MXPA02005959A (es) 2003-10-14

Similar Documents

Publication Publication Date Title
AU7720496A (en) The use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
NO991951L (no) Tienopyrimidiner med fosfodiesterase V-inhiberende virkning
BR0108175A (pt) Derivados de piperazina e piperidina para o tratamento ou a prevenção de danos neuronais
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
NO976142D0 (no) Anvendelse av minst en NO syntase inhibitor i behandling av fölsom hud
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
GR20010300006T1 (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
HK1155944A1 (en) W-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
BR0213975A (pt) Métodos para tratar doenças neovasculares oculares
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
NO20002702L (no) Tienopyrimidiner
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
BR0016415A (pt) Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
SE0102147D0 (sv) New methods
MX9601149A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del prurito y de las disestesias oculares o palpebrales y composicion que incluye dicho antagonista.
DE69920033D1 (de) Verfahren zur verminderung von krebssymptomen
DK0435177T3 (da) 4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-oner samt deres anvendelse som antikonvulsive midler
BR9915803A (pt) Composição para o tratamento de neuropatia da retina ou cabeça de nervo ótico, e, processo para tratamento de neuropatia da retina ou cabeça de nervo ótico
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
BR0214564A (pt) Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
WO2001002358A3 (en) Cyclized amide derivatives for treating or preventing neuronal damage

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]